CR9979A - Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer - Google Patents

Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer

Info

Publication number
CR9979A
CR9979A CR9979A CR9979A CR9979A CR 9979 A CR9979 A CR 9979A CR 9979 A CR9979 A CR 9979A CR 9979 A CR9979 A CR 9979A CR 9979 A CR9979 A CR 9979A
Authority
CR
Costa Rica
Prior art keywords
chemotherapy
modifying agents
transcript
against cancer
radiotherapy
Prior art date
Application number
CR9979A
Other languages
English (en)
Inventor
Gonzalez Alfonso Duenas
Flores Luis Estrada
Original Assignee
Univ Mexico Nacional Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mexico Nacional Autonoma filed Critical Univ Mexico Nacional Autonoma
Publication of CR9979A publication Critical patent/CR9979A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con el uso de agentes modificantes del transcriptoma con el objetivo de impedir a las células malignas realizar los cambios génicos necesarios para hacer frente al insulto celular y sobrevivir a la quimioterapia o radioterapia.
CR9979A 2005-11-16 2008-05-16 Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer CR9979A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2005/000106 WO2007075077A1 (es) 2005-11-16 2005-11-16 Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer

Publications (1)

Publication Number Publication Date
CR9979A true CR9979A (es) 2009-08-24

Family

ID=38218257

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9979A CR9979A (es) 2005-11-16 2008-05-16 Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer

Country Status (12)

Country Link
US (1) US9186339B2 (es)
EP (1) EP1949898A1 (es)
JP (1) JP2009519898A (es)
CN (1) CN101355934A (es)
AR (1) AR058192A1 (es)
AU (1) AU2005339587B2 (es)
BR (1) BRPI0520686A2 (es)
CA (1) CA2630334C (es)
CR (1) CR9979A (es)
PE (1) PE20070722A1 (es)
UY (1) UY29901A1 (es)
WO (1) WO2007075077A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
WO2011097317A1 (en) * 2010-02-02 2011-08-11 Progen Pharmaceuticals, Inc. Use of n1,n4-bis[3-(ethylamino)propyl]-2-butene-1,4-diamine compounds in combination with epigenetic-acting pharmaceuticals for enhanced cancer therapy
JP2017537622A (ja) * 2014-12-02 2017-12-21 ロジャー・ウィリアムズ・ホスピタル がんを治療するための方法及び組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300373B1 (en) * 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
US6713043B2 (en) * 1996-02-29 2004-03-30 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
MXPA05000485A (es) * 2002-07-11 2005-04-19 Combinatorx Inc Combinacion de farmacos para el tratamiento de neoplasmas.
WO2004035045A1 (en) * 2002-10-16 2004-04-29 Pharmacia Italia S.P.A. Use of substituted acrylolyl distamycin derivatives in combination with demethylating agents, in the treatment of cancer
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
PL1591109T3 (pl) * 2004-04-30 2008-11-28 Topotarget Germany Ag Preparat zawierający inhibitor deacetylazy histonów wykazujący dwufazowe uwalnianie”

Also Published As

Publication number Publication date
PE20070722A1 (es) 2007-09-28
US9186339B2 (en) 2015-11-17
CA2630334A1 (en) 2007-07-05
AU2005339587A1 (en) 2007-07-05
US20090196851A1 (en) 2009-08-06
AU2005339587A8 (en) 2008-07-24
AU2005339587B2 (en) 2011-11-03
JP2009519898A (ja) 2009-05-21
AR058192A1 (es) 2008-01-23
EP1949898A1 (en) 2008-07-30
WO2007075077A1 (es) 2007-07-05
WO2007075077A8 (es) 2008-11-20
CN101355934A (zh) 2009-01-28
BRPI0520686A2 (pt) 2009-05-19
CA2630334C (en) 2013-07-23
UY29901A1 (es) 2007-04-30

Similar Documents

Publication Publication Date Title
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
CL2022002974A1 (es) Métodos de administración celular in vitro
UY31105A1 (es) Predicción pronóstica del melanoma
AR060241A1 (es) Composiciones y metodos de uso para anticuerpos de c-met
BRPI0613770A2 (pt) anticorpos anti-cd26 e métodos de uso destes
CO2021006493A2 (es) Terapia del cáncer con células inmunitarias anti-liv1
EP3683321A3 (en) Methods relating to circulating tumor cell clusters and the treatment of cancer
EP1786905A4 (en) SMALL INTERFERING RNA MOLECULES AGAINST RIBONUCLEOTIDE REDUCTASE AND ITS USES
CL2011003022A1 (es) Compuestos derivados de 2,4 diaminopirimidina, inhibidores de quinasa ptk2; composicion farmaceutica que comprende a uno de los compuestos, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva, tal como cancer.
MX2020006901A (es) Composiciones de pares de bases no naturales y procedimientos de uso.
WO2007012811A3 (en) Prostate stem cell markers
CR9853A (es) Compuestos de exemestano (s)-6-metiloxaalquilo y metodos relacionados con su utilizacion
ATE543834T1 (de) Mit pancreaskrebs assoziierte genfamilie (lbfl313)
CR9979A (es) Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer
ATE543097T1 (de) Zellulärer rezeptor für antiproliferativen faktor
ATE533861T1 (de) Mipol1-etv1-gen-neuanordnungen
ATE556446T1 (de) Batterieanoden
EP3581660A3 (en) Niche targeting of quiescent cancer stem cells
AU323809S (en) Shoe
CL2008003652A1 (es) Uso de tribendimidina para combatir endoparasitos en ganado productivo.
UY31449A1 (es) Propagacion de ortomixoviridae
JP1756601S (ja) 携帯電話機
ECSP088454A (es) Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer
WO2020099938A3 (en) Methods and compositions for characterizing bladder cancer
AU308295S (en) Radio